NEWSROOM

Chronic Obstructive Pulmonary Disease

KALY – Kali Extracts Confirms Analyst Report On Cannabis Extract Biopharmaceutical Strategy Scheduled For Publication Next Week

          DALLAS, Aug. 23, 2019-- -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the publication of an analyst report covering the company’s overall cannabis extract biopharmaceutical strategy is scheduled for next week on Wednesday, August 28, 2019. After making a strategic acquisition in Q4 2018 of a business with a U.S. Patented Cannabis Extraction Process, KALY has just posted its 2019 YTD financials reporting 250% revenue growth. The...

read more

KALY – Kali-Extracts Confirms Corporate Up-To-Date Financials Scheduled For Publication This Thursday And RespRx Website Coming Friday

Dallas, TX – Aug 20, 2019 -- -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company intends to publish up-to-date corporate financials on Thursday, August 22nd.  The company also plans to publish a website on Friday, August 23rd, dedicated to its new CBD formulation, RespRx, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.  The KALY management commitments to...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »